Home > Insider Trading > Filing (0001209191-16-137368)

Filing Details

Accession Number:: 0001209191-16-137368
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-08-16 19:16:56
Reporting Period:: 2016-07-14

Filing Date:: 2016-08-16
Accepted Time:: 2016-08-16 19:16:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
895051	Casi Pharmaceuticals Inc.	CASI	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
831547	Spectrum Pharmaceuticals Inc	11500 S. Eastern Ave. Suite 240 Henderson NV 89052		No	No	Yes	No
1619860	Spectrum Pharmaceuticals Cayman, L.p.	11500 S. Eastern Ave. Suite 240 Henderson NV 89052		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-14	585,790	$0.01	4,823,181	No	4	P	Direct
Common Stock	Acquisiton	2016-07-20	98,271	$0.01	4,921,452	No	4	P	Direct
Common Stock	Acquisiton	2016-07-14	394,942	$0.01	3,251,810	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2016-07-20	66,255	$0.01	3,318,065	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

Pursuant to Investment Agreements, dated Sept. 17, 2014 ("Closing Date"), Spectrum Pharmaceuticals, Inc., a Delaware corporation ("Spectrum") and Spectrum Pharmaceuticals Cayman, L.P. ("Spectrum Cayman"), were issued a contingent right to purchase shares of the Issuer's Common Stock, at par value, in order to maintain their respective post-investment equity ownership percentage as of the Closing Date (the "Contingent Right"), in the event Issuer issued securities (subject to limited exceptions) after the Closing Date. On June 24, 2016, the Issuer consummated the second tranche of a private placement of 4,906,118 shares of Common Stock and 981,223 warrants to certain Investors, which triggered the Contingent Right to Spectrum and Spectrum Cayman to purchase, in the aggregate, 980,732 shares of the Issuer's Common Stock. Spectrum and Spectrum Cayman exercised the Contingent Right and on July 14, 2016, the Issuer issued 585,790 shares to Spectrum and 394,942 shares to Spectrum Cayman.
On July 5, 2016, the Issuer consummated the third tranche of a private placement of 823,045 shares of Common Stock and 164,609 warrants to certain Investors, which triggered the Contingent Right to Spectrum and Spectrum Cayman to purchase, in the aggregate, 164,526 shares of the Issuer's Common Stock. Spectrum and Spectrum Cayman exercised the Contingent Right and, on July 20, 2016, the Issuer issued 98,271 shares to Spectrum and 66,255 shares to Spectrum Cayman
These securities are owned directly by Spectrum Cayman, which is owned 99% by Spectrum and 1% by Spectrum Pharmaceuticals International Holdings, LLC, a Delaware limited liability company. As a result, Spectrum may be deemed to share voting and dispositive power over the reported securities. Spectrum disclaims beneficial ownership in the shares held directly by Spectrum Cayman except to the extent of its pecuniary interest therein.